Failure of bamlanivimab with selection of E484K mutation in an allogeneic stem cell transplant recipient with nosocomial SARS-CoV-2 infection

Antiviral Therapy · Published 2024-02-01 · DOI 10.1177/13596535221097495

Authors being retrieved — see the publisher record. https://doi.org/10.1177/13596535221097495

Abstract

We report the case of an allogeneic stem cell transplant recipient with nosocomial acquisition of SARS-CoV-2 infection who received antispike neutralizing monoclonal antibody bamlanivimab 2 days after diagnosis of SARS-CoV-2 infection but progressed to severe COVID-19 pneumonia and died with the selection of E484K/Q resistance mutations to bamlanivimab.

Abstract from DOAJ. Public domain (CC0 1.0).

Read the article at the publisher →

Publication details

Year

2024

Related articles

• Fanconi syndrome, diabetes insipidus, and acute kidney injury due to tenofovir disoproxil fumarate: A case report · Antiviral Therapy · 2023 · Same journal
• Sustained viral suppression with once daily dolutegravir-containing regimen in presence of the strong inducer carbamazepine · Antiviral Therapy · 2025 · Same journal
• Analysis of risk factors and prediction model construction for varicella encephalitis in children: A retrospective cohort study · Antiviral Therapy · 2024 · Same journal
• Case report and literature review: A hiccup patient developed encephalitis and duodenal perforation · Antiviral Therapy · 2023 · Same journal
• Andrographolide inhibits infectious bronchitis virus-induced apoptosis, pyroptosis, and inflammation · Antiviral Therapy · 2023 · Same journal
• Comparative efficacy and safety of tenofovir amibufenamide vs tenofovir alafenamide in the initial 48-week treatment of high viral load chronic hepatitis B: A single-centre retrospective study · Antiviral Therapy · 2024 · Same journal
• Cross-resistance to entry inhibitors and lenacapavir resistance through Week 52 in study CAPELLA · Antiviral Therapy · 2023 · Same journal
• Socioeconomic status largely explains integrase inhibitors-related body composition differences in chronically infected men living with HIV · Antiviral Therapy · 2022 · Same journal
• Andrographolide suppresses SARS-CoV-2 infection by downregulating ACE2 expression: A mechanistic study · Antiviral Therapy · 2024 · Same journal
• Understanding the effect of direct-acting antiviral therapy on weight in patients with chronic hepatitis C · Antiviral Therapy · 2022 · Same journal